Tirzepatide Mechanism of Action

*Receptor pharmacology of the dual GIP/GLP-1 receptor agonist tirzepatide: imbalanced agonism, downstream signalling differences from semaglutide, and the metabolic consequences of GIP arm activation.*

Research Use Only. All material on this page is provided strictly for in vitro and in vivo laboratory research purposes. It is not medical advice and is not intended for human or veterinary therapeutic use.

Overview

Tirzepatide is a synthetic 39-amino-acid linear peptide engineered from the native GIP sequence with substitutions that confer activity at both the GIP and GLP-1 receptors. A C20 fatty diacid moiety provides albumin anchoring for a half-life of approximately 120 hours.

Receptor Profile

• GIP receptor: full agonist; affinity comparable to native GIP
• GLP-1 receptor: partial-to-full agonist depending on assay readout; lower potency than native GLP-1
• "Imbalanced" agonism: receptor pharmacology favours GIP — the molecule is sometimes described as "GIP-leaning"

Downstream Signalling

• GIP-R: Gαs → cAMP → PKA in pancreatic β-cells (insulinotropic) and adipocytes (lipogenic / lipolytic depending on context)
• GLP-1R: Gαs / cAMP / PKA + arcuate appetite suppression
• The dual-receptor activation appears to produce additive insulinotropic effect and complementary central satiety signalling

Physiological Effects

• Pancreas: glucose-dependent insulin secretion and glucagon suppression
• Adipose tissue: GIP-mediated effects on adipocyte lipid storage and energy partitioning are a hypothesised contributor to the superior weight-loss efficacy vs semaglutide
• CNS: GIP-R and GLP-1R are both expressed in hindbrain and hypothalamic appetite centres
• GI: delayed gastric emptying (GLP-1 mediated)

Pharmacokinetics

• t½: ~120 h
• Tmax: 8–72 h post SC injection
• Distribution: >99% albumin-bound
• Metabolism: proteolytic cleavage; no CYP involvement
• Excretion: as fragments in urine and feces

SURPASS-2 Head-to-Head Reference

In SURPASS-2 (NEJM 2021) tirzepatide 15 mg weekly produced greater HbA1c reduction (–2.30%) and weight loss (–11.2 kg) than semaglutide 1 mg weekly (–1.86%, –5.7 kg) over 40 weeks, supporting the hypothesis that GIP-arm activation contributes mechanistically distinct metabolic effects.

Frequently Asked Research Questions

Is tirzepatide a balanced GIP/GLP-1 agonist?

No. Published receptor-binding data show tirzepatide is closer in potency to native GIP at GIP-R than to native GLP-1 at GLP-1R, producing what the developers describe as 'imbalanced' or GIP-leaning agonism.

Why might GIP-arm activation help weight loss?

GIP-R is expressed in adipocytes and hindbrain appetite regions. Preclinical work suggests GIP agonism reshapes adipocyte lipid handling and contributes to central satiety, complementing the GLP-1 satiety pathway.

How does tirzepatide compare to semaglutide head-to-head?

SURPASS-2 showed superior HbA1c and weight outcomes for tirzepatide 15 mg vs semaglutide 1 mg over 40 weeks. Comparison with semaglutide 2.4 mg (the obesity dose) has not been published in a head-to-head trial.

References

1. Drucker DJ. *Mechanisms of action and therapeutic application of GLP-1.* Cell Metab. 2018.

1. Coskun T, et al. *LY3298176 (tirzepatide) — discovery of a dual GIP/GLP-1 agonist.* Mol Metab. 2018.

1. Sikiric P, et al. *Stable gastric pentadecapeptide BPC-157.* Curr Pharm Des. 2018.

1. Goldstein AL, Hannappel E. *Thymosin β4 — actin sequestering and tissue repair.* Ann N Y Acad Sci. 2007.

1. Falutz J, et al. *Tesamorelin in HIV-associated lipodystrophy.* N Engl J Med. 2007.

1. Pfaus JG, et al. *Bremelanotide — central melanocortin agonism.* Curr Sex Health Rep. 2007.

1. Khavinson VK, et al. *Epitalon — pineal-tetrapeptide telomerase activation.* Bull Exp Biol Med. 2003.

1. Imai S, Guarente L. *NAD+ and sirtuins in aging and disease.* Trends Cell Biol. 2014.